No Prescription |
 |
 | ||
|
Alphagan Z Generic Brimonidine Tartrate Ophthalmic solution |
|
| ||
No Prescription » Prescription Drugs 1 » Alphagan Z Generic Brimonidine Tartrate Ophthalmic solution INDICATIONS AND USAGE:ALPHAGAN« Z is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.DOSAGE AND ADMINISTRATION:The recommended dose is one drop of ALPHAGAN« Z in the affected eye(s) three times daily approximately 8 hours apart. ALPHAGAN« Z ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. Buy Alphagan Z Generic Brimonidine Tartrate Ophthalmic solution and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Alphagan Z Generic Brimonidine Tartrate Ophthalmic solution: Product Type: Prescription Drugs 1 Alphagan Z (Generic Brimonidine Tartrate Ophthalmic solution) Alphagan Z (Generic Brimonidine Tartrate Ophthalmic solution) Generic Brimonidine Tartrate Ophthalmic solution 0.1%w/v 5mL 15mL(3 x 5mL) 30mL(6 x 5mL) Generic Brimonidine Tartrate Ophthalmic solution Alphagan Z
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
